Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the interest coverage ratio high or low?
The interest coverage ratio of -2.35x is 32% above its 5-year average of -3.45x, near the high end of its 5-year range (-28.12x–-0.26x).
96.75% below its 12-month average of -1.19x.
Reported quarterly interest coverage; no daily interpolation. Q2 FY2026 (2026-06-30): -0.26x.
INTEREST COVERAGE RATIO
-2.35x
INTEREST COVERAGE RATIO AVG TTM
-1.19x
INTEREST COVERAGE RATIO AVG 3Y
-2.92x
INTEREST COVERAGE RATIO AVG 5Y
-3.45x
INTEREST COVERAGE RATIO AVG 10Y
N/A
INTEREST COVERAGE RATIO AVG 15Y
N/A
INTEREST COVERAGE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-96.75%
CURRENT VS 3Y AVG
+19.55%
CURRENT VS 5Y AVG
+31.93%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-5.64x
median of 453 covered companies
CURRENT VS SECTOR MEDIAN
+58.33%
vs the sector median at left
Phathom Pharmaceuticals, Inc.
Market Cap
$542.85M
Interest Coverage Ratio
-2.35x
TTM Avg
-1.19x
3Y Avg
-2.92x
5Y Avg
-3.45x
Market Cap
$541.30M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$536.32M
Interest Coverage Ratio
-41251.75x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$534.86M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$554.29M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$552.89M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$554.85M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$560.00M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$522.93M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. (PHAT) | $542.85M | -2.35x | -1.19x | -2.92x | -3.45x |
| Delcath Systems, Inc. (DCTH)vs › | $541.30M | N/A | N/A | N/A | N/A |
| ProKidney Corp. (PROK)vs › | $536.32M | -41251.75x | N/A | N/A | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $534.86M | N/A | N/A | N/A | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $554.29M | N/A | N/A | N/A | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $552.89M | N/A | N/A | N/A | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $554.85M | N/A | N/A | N/A | N/A |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $522.93M | N/A | N/A | N/A | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $522.80M | -69.85x | N/A | N/A | N/A |
Interest Coverage
-2.4x
Debt/Equity
N/A
Current Ratio
1.92
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | INTEREST COVERAGE RATIO |
|---|---|
| 2026-06-30 | -0.26x |
| 2026-03-31 | -0.98x |
| 2025-12-31 | -0.36x |
| 2025-09-30 | -0.95x |
| 2025-06-30 | -3.42x |
| 2025-03-31 | -4.36x |
| 2024-12-31 | -3.20x |
| 2024-09-30 | -3.83x |
| 2024-06-30 | -4.35x |
| 2024-03-31 | -4.07x |
| 2023-12-31 | -5.36x |
| 2023-09-30 | -3.53x |
| 2023-06-30 | -3.30x |
| 2023-03-31 | -3.26x |
| 2022-12-31 | -4.86x |
| 2022-09-30 | -4.58x |
| 2022-06-30 | -8.00x |
| 2022-03-31 | -13.74x |
| 2021-12-31 | -11.91x |
| 2021-09-30 | -22.31x |
| 2021-06-30 | -28.12x |
| 2021-03-31 | -26.40x |
| 2020-12-31 | -40.46x |
| 2020-09-30 | -25.53x |
| 2020-06-30 | -15.86x |
| 2020-03-31 | -27.61x |
| 2019-12-31 | -15.10x |
| 2019-09-30 | -3.16x |
| 2019-06-30 | -73.01x |
| 2019-03-31 | -111.45x |
| 2018-12-31 | -90.20x |
| 2018-09-30 | -67.00x |
